Gilead Sciences, Inc. $GILD Shares Purchased by Oliver Luxxe Assets LLC

Key Points

• Oliver Luxxe Assets LLC increased its holdings in Gilead Sciences, Inc. by 5.3% in the second quarter, now owning a total of 62,465 shares valued at approximately $6.93 million.
• Gilead Sciences reported earnings of $2.01 per share, exceeding analysts' expectations, with quarterly revenue reaching $7.08 billion.
• The company announced a quarterly dividend of $0.79 per share, resulting in an annualized yield of 2.8%.

Oliver Luxxe Assets LLC increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 5.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 62,465 shares of the biopharmaceutical company's stock after purchasing an additional 3,156 shares during the period. Gilead Sciences makes up 1.2% of Oliver Luxxe Assets LLC's holdings, making the stock its 19th biggest position. Oliver Luxxe Assets LLC's holdings in Gilead Sciences were worth $6,925,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD increased its holdings in shares of Gilead Sciences by 314.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company's stock valued at $1,647,484,000 after purchasing an additional 11,156,382 shares in the last quarter. Nuveen LLC purchased a new position in Gilead Sciences in the first quarter valued at $620,415,000. GAMMA Investing LLC raised its position in shares of Gilead Sciences by 13,891.1% in the first quarter. GAMMA Investing LLC now owns 2,550,298 shares of the biopharmaceutical company's stock worth $285,761,000 after acquiring an additional 2,532,070 shares during the period. Kingstone Capital Partners Texas LLC acquired a new position in shares of Gilead Sciences in the second quarter worth about $238,083,000. Finally, Los Angeles Capital Management LLC boosted its stake in shares of Gilead Sciences by 422.6% during the 1st quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company's stock worth $282,706,000 after acquiring an additional 2,040,261 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

Shares of GILD opened at $114.09 on Monday. The firm has a 50-day simple moving average of $114.10 and a two-hundred day simple moving average of $109.98. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. Gilead Sciences, Inc. has a 1-year low of $81.83 and a 1-year high of $121.83. The stock has a market cap of $141.56 billion, a PE ratio of 22.73, a P/E/G ratio of 0.77 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.08 billion for the quarter, compared to analysts' expectations of $6.95 billion. During the same quarter in the prior year, the company earned $2.01 earnings per share. The business's quarterly revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.8%. The ex-dividend date is Monday, September 15th. Gilead Sciences's payout ratio is 62.95%.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. JPMorgan Chase & Co. lifted their price target on Gilead Sciences from $135.00 to $145.00 and gave the company an "overweight" rating in a research note on Tuesday, September 16th. Royal Bank Of Canada raised their price objective on Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a report on Friday, August 8th. Daiwa America raised Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, August 19th. Rothschild & Co Redburn increased their target price on Gilead Sciences from $136.00 to $143.00 and gave the company a "buy" rating in a research report on Friday, September 12th. Finally, Dbs Bank raised shares of Gilead Sciences to a "moderate buy" rating in a research note on Friday, September 5th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat, Gilead Sciences has a consensus rating of "Moderate Buy" and a consensus target price of $117.17.

Insider Activity

In related news, CEO Daniel Patrick O'day sold 10,000 shares of the stock in a transaction on Thursday, August 28th. The stock was sold at an average price of $113.63, for a total value of $1,136,300.00. Following the transaction, the chief executive officer owned 595,725 shares of the company's stock, valued at $67,692,231.75. This represents a 1.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $340,710.00. Following the sale, the insider directly owned 113,193 shares of the company's stock, valued at $12,855,329.01. This trade represents a 2.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 82,000 shares of company stock worth $9,390,030. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.